Diffuse Large B-cell Lymphoma
Results from the phase II trial REAL07 were presented at the 2013 American Society of Hematology 2013 annual meeting. The trial was designed to demonstrate an improvement of overall response rate of 15% in patients receiving LRCHOP21
(lenalidomide, rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) compared with 70% with standard RCHOP21. Elderly patients with untreated diffuse large B-cell lymphoma were enrolled in the trial. Following six courses of LRCHOP21, overall response rate was 92%. At a median follow-up of 28 months, two-year overall survival was 92%, two-year progression-free survival 80% and two-year event-free survival 70%.
For more information, click here.